Welcome to Multibagg AI
Log in to access personalized features
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Kopran Ltd (KOPRAN) is currently trading at 123.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd. Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition. The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards. Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.
Over the past 52 weeks, Kopran Ltd has traded between a low of ₹119.60 and a high of ₹214.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kopran Ltd has a market capitalization of approximately 613.71. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kopran Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.96 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 613.71 Cr, Kopran Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kopran Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kopran Ltd is 35.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
345.65 | 829 Cr | 22.00 | 3.53 | 0.29 | 13.89 | 19.49 | 12.00 | |
19.87 | 759 Cr | -10.19 | 1.50 | 0.50 | 12.11 | 12.71 | -8.73 | |
81.97 | 755 Cr | -43.41 | 2.18 | 0.61 | -7.10 | -3.47 | -2.99 | |
506.00 | 644 Cr | 35.94 | 4.19 | 0.00 | 13.30 | 16.18 | 8.86 | |
127.70 | 614 Cr | 37.34 | 1.22 | 2.36 | 3.51 | 5.38 | 2.04 | |
685.90 | 392 Cr | 40.75 | 0.99 | 0.73 | -3.83 | -3.33 | 1.80 | |
100.10 | 389 Cr | 26.98 | 1.84 | 0.00 | 7.41 | 11.89 | 3.14 |
Scheme of Arrangement
NSE issued an observation letter (Feb 27, 2026) conveying 'No Objection' under Reg 37 for Kopran Limited's draft scheme of amalgamation with Kopran Laboratories, subject to SEBI/exchange observations, statutory compliances and other approvals.
Scheme of Arrangement
BSE issued an observation letter dated Feb 26, 2026 with 'no adverse observations' for the proposed merger by absorption of Kopran Laboratories Ltd into Kopran Limited; SEBI/Exchange provided disclosure conditions and the scheme remains subject to regulatory approvals.
Bearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd.
Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition.
The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards.
Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
614 Cr
High Risk
36.0
28.4
1.1
1.2
214.65
119.60
Sales CAGR
Profit CAGR
ROE
ROCE
